OBJECTIVE: We performed a population-based analysis to compare the clinical characteristics of women with mucinous tumors with women with other epithelial tumors. STUDY DESIGN: The Surveillance, Epidemiology, and End Results database was queried to identify all women with epithelial ovarian cancer diagnosed from 1988 to 2007. The natural history, clinical characteristics, and survival of women with serous tumors were compared with women with mucinous carcinomas. RESULTS: A total of 40,571 women including 4811 with mucinous carcinomas (11.9%) were identified. Among women with stage I neoplasms, the presence of mucinous histology had no effect on either cancer-specific survival (hazard ratio, 0.87; 95% confidence interval, 0.74-1.04). Survival was inferior in patients with advanced-stage mucinous compared with serous tumors. The hazard ratio for cancer-specific survival for women with stage III mucinous tumors was 1.55 (95% confidence interval, 1.43-1.96). CONCLUSION: Although survival for early-stage mucinous and serous tumors is similar, survival for advanced-stage mucinous neoplasms is inferior to that of serous carcinomas.
OBJECTIVE: We performed a population-based analysis to compare the clinical characteristics of women with mucinous tumors with women with other epithelial tumors. STUDY DESIGN: The Surveillance, Epidemiology, and End Results database was queried to identify all women with epithelial ovarian cancer diagnosed from 1988 to 2007. The natural history, clinical characteristics, and survival of women with serous tumors were compared with women with mucinous carcinomas. RESULTS: A total of 40,571 women including 4811 with mucinous carcinomas (11.9%) were identified. Among women with stage I neoplasms, the presence of mucinous histology had no effect on either cancer-specific survival (hazard ratio, 0.87; 95% confidence interval, 0.74-1.04). Survival was inferior in patients with advanced-stage mucinous compared with serous tumors. The hazard ratio for cancer-specific survival for women with stage III mucinous tumors was 1.55 (95% confidence interval, 1.43-1.96). CONCLUSION: Although survival for early-stage mucinous and serous tumors is similar, survival for advanced-stage mucinous neoplasms is inferior to that of serous carcinomas.
Authors: Erin M George; Thomas J Herzog; Alfred I Neugut; Yu-Shiang Lu; William M Burke; Sharyn N Lewin; Dawn L Hershman; Jason D Wright Journal: Gynecol Oncol Date: 2013-07-06 Impact factor: 5.482
Authors: Lauren C Peres; Kara L Cushing-Haugen; Michael Anglesio; Kristine Wicklund; Rex Bentley; Andrew Berchuck; Linda E Kelemen; Tayyebeh M Nazeran; C Blake Gilks; Holly R Harris; David G Huntsman; Joellen M Schildkraut; Mary Anne Rossing; Martin Köbel; Jennifer A Doherty Journal: Gynecol Oncol Date: 2018-08-16 Impact factor: 5.482
Authors: Robertson Mackenzie; Aline Talhouk; Sima Eshragh; Sherman Lau; Daphne Cheung; Christine Chow; Nhu Le; Linda S Cook; Nafisa Wilkinson; Jacqueline McDermott; Naveena Singh; Friedrich Kommoss; Jacobus Pfisterer; David G Huntsman; Martin Köbel; Stefan Kommoss; C Blake Gilks; Michael S Anglesio Journal: Am J Surg Pathol Date: 2015-11 Impact factor: 6.394
Authors: Koji Matsuo; Yongmei Huang; Oliver Zivanovic; Muneaki Shimada; Hiroko Machida; Brendan H Grubbs; Lynda D Roman; Jason D Wright Journal: Gynecol Oncol Date: 2019-07-04 Impact factor: 5.482
Authors: Helen E Dinkelspiel; Miriam Champer; June Hou; Ana Tergas; William M Burke; Yongmei Huang; Alfred I Neugut; Cande V Ananth; Dawn L Hershman; Jason D Wright Journal: Gynecol Oncol Date: 2015-06-05 Impact factor: 5.482
Authors: Vijaya Galic; Maria B Schiavone; Thomas J Herzog; Kevin Holcomb; Sharyn N Lewin; Yu-Shiang Lu; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Cancer Invest Date: 2013-08 Impact factor: 2.176
Authors: Sang Kyum Kim; Si Young Song; Sunghoon Kim; Nam Hoon Cho; Ga Won Yim; Sang Wun Kim; Young Tae Kim; Eun Ji Nam Journal: Int J Clin Exp Pathol Date: 2014-07-15
Authors: Koji Matsuo; Hiroko Machida; Shinya Matsuzaki; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson; Jason D Wright Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482